And maybe they've sorted the potency assay.
But that doesn't mean the previous trial is now sufficient. You would often need to validate that potency assay in a prospective rather than retrospective way - hence why I suspect they'll be relying on the adult trial for both paeds and adults.
MSB said in another announcement they would be linking the potency to the adult trial to validate.
I suspect FDA will require this. But maybe I'm wrong.
And maybe they've sorted the potency assay.But that...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
93.0¢ |
Change
0.015(1.64%) |
Mkt cap ! $1.061B | |||
| Open | High | Low | Value | Volume |
| 92.5¢ | 95.0¢ | 89.0¢ | $7.902M | 8.522M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2945 | 92.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 93.0¢ | 40422 | 4 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
93.0¢ |
Change
0.015 ( 2.54 %) |
||||
| Open | High | Low | Volume | ||
| 92.0¢ | 95.0¢ | 89.5¢ | 2254102 | ||
| Last updated 15.59pm 26/04/2024 ? | |||||
| MSB (ASX) Chart |